Metraipolis › archive › dc_7d1bf4ce6f4e

Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer — Europe PMC PMID:42450152

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42450152
DOI: 10.3390/ijms27135883
License (as archived): solo-consultazione
Archived: 2026-10-18T14:49:21.973Z
SHA-256 of the archived text: 78067d4b680c6ad5c96e5a8eee14a8f717de0f11ddf199a3ee50cae296d46dc1
Stable URL of this page: https://metraipolis.com/documento/dc_7d1bf4ce6f4e

How to cite

Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer — Europe PMC PMID:42450152 — Europe PMC (en), https://europepmc.org/article/MED/42450152 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7d1bf4ce6f4e (Metraipolis archive dc_7d1bf4ce6f4e, sha256 78067d4b680c6ad5c96e5a8eee14a8f717de0f11ddf199a3ee50cae296d46dc1)

BibTeX

@misc{dc7d1bf4ce6f4e,
  title = {Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer — Europe PMC PMID:42450152},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42450152},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7d1bf4ce6f4e; sha256 78067d4b680c6ad5c96e5a8eee14a8f717de0f11ddf199a3ee50cae296d46dc1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42450152. Agents can read the archived copy with the MCP tool read_document.